A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile
Clinical trial NCT02702388 · COMPLETED
Trial details
- NCT number
- NCT02702388
- Sponsor
- Eisai Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-08
- Primary completion
- 2019-12-12
- Enrollment
- 241
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.